<VariationArchive VariationID="17881" VariationName="NM_000384.3(APOB):c.5263_5266del (p.Asn1755fs)" VariationType="Deletion" Accession="VCV000017881" Version="12" RecordType="classified" NumberOfSubmissions="3" NumberOfSubmitters="3" DateLastUpdated="2024-07-29" DateCreated="2013-12-12" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="32920" VariationID="17881">
      <GeneList>
        <Gene Symbol="APOB" FullName="apolipoprotein B" GeneID="338" HGNC_ID="HGNC:603" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>2p24.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="21001429" stop="21044073" display_start="21001429" display_stop="21044073" Strand="-" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NW_025791767.1" start="52097" stop="94741" display_start="52097" display_stop="94741" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="21224300" stop="21266944" display_start="21224300" display_stop="21266944" Strand="-" />
          </Location>
          <OMIM>107730</OMIM>
          <Haploinsufficiency last_evaluated="2020-04-09" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=APOB">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-04-09" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=APOB">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000384.3(APOB):c.5263_5266del (p.Asn1755fs)</Name>
      <CanonicalSPDI>NC_000002.12:21011601:TGTTTGT:TGT</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>2p24.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="21011602" stop="21011605" display_start="21011602" display_stop="21011605" variantLength="4" positionVCF="21011601" referenceAlleleVCF="CTGTT" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="21234474" stop="21234477" display_start="21234474" display_stop="21234477" variantLength="4" positionVCF="21234473" referenceAlleleVCF="CTGTT" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>N1755fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_011793.1" sequenceAccession="NG_011793" sequenceVersion="1" change="g.37469_37472del">
            <Expression>NG_011793.1:g.37469_37472del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.21234477_21234480del" Assembly="GRCh37">
            <Expression>NC_000002.11:g.21234477_21234480del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.21011605_21011608del" Assembly="GRCh38">
            <Expression>NC_000002.12:g.21011605_21011608del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000384.3" sequenceAccession="NM_000384" sequenceVersion="3" change="c.5263_5266del" MANESelect="true">
            <Expression>NM_000384.3:c.5263_5266del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000375.3" sequenceAccession="NP_000375" sequenceVersion="3" change="p.Asn1755fs">
            <Expression>NP_000375.3:p.Asn1755fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="CA022852" DB="ClinGen" />
        <XRef Type="Allelic variant" ID="107730.0001" DB="OMIM" />
        <XRef Type="rs" ID="281865425" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000384.3(APOB):c.5263_5266del (p.Asn1755fs) AND Familial hypobetalipoproteinemia" Accession="RCV000019470" Version="33">
        <ClassifiedConditionList TraitSetID="5927">
          <ClassifiedCondition DB="MedGen" ID="C1862596">Familial hypobetalipoproteinemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1992-12-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000384.3(APOB):c.5263_5266del (p.Asn1755fs) AND multiple conditions" Accession="RCV001837436" Version="15">
        <ClassifiedConditionList TraitSetID="19838">
          <ClassifiedCondition DB="MedGen" ID="C4551990">Familial hypobetalipoproteinemia 1</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1704417">Hypercholesterolemia, autosomal dominant, type B</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2021-11-09" SubmissionCount="2">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-11-09" NumberOfSubmissions="3" NumberOfSubmitters="3" DateCreated="2013-12-12" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">1454832</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20032471</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">221546</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">3399894</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">3473077</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="5927" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="12931" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Hypobetalipoproteinemia, familial, associated with apob39</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hypobetalipoproteinemia, familial, associated with apob40</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hypobetalipoproteinemia, familial, associated with apob90 or apob89</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hypobetalipoproteinemia, familial, associated with apob46</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hypobetalipoproteinemia, familial, associated with apob87</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hypobetalipoproteinemia, familial, associated with apob31</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Familial hypobetalipoproteinemia</ElementValue>
                <XRef ID="60193003" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">FHBL</ElementValue>
              </Symbol>
              <XRef ID="426" DB="Orphanet" />
              <XRef ID="C1862596" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="19838" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1725" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">APOLIPOPROTEIN B-100, FAMILIAL DEFECTIVE</ElementValue>
                <XRef Type="MIM" ID="144010" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">APOLIPOPROTEIN B-100, FAMILIAL LIGAND-DEFECTIVE</ElementValue>
                <XRef Type="MIM" ID="144010" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Familial Hypercholesterolemia Type B</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyperlipoproteinemia Type IIb</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Familial hypercholesterolemia 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hypercholesterolemia, autosomal dominant, type B</ElementValue>
                <XRef ID="MONDO:0007751" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">HYPERCHOLESTEROLEMIA, FAMILIAL, DUE TO LIGAND-DEFECTIVE APOLIPOPROTEIN B</ElementValue>
                <XRef Type="MIM" ID="144010" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">FHCL2</ElementValue>
                <XRef Type="MIM" ID="144010" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Familial hypercholesterolemia (FH) is characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) that leads to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age and increases the risk of premature cardiovascular events such as angina and myocardial infarction; stroke occurs more rarely. Xanthomas (cholesterol deposits in tendons) may be visible in the Achilles tendons or tendons of the hands and worsen with age as a result of extremely high cholesterol levels. Xanthelasmas (yellowish, waxy deposits) can occur around the eyelids. Individuals with FH may develop corneal arcus (white, gray, or blue opaque ring in the corneal margin as a result of cholesterol deposition) at a younger age than those without FH. Individuals with a more severe phenotype, often as a result of biallelic variants, can present with very significant elevations in LDL-C (&gt;500 mg/dL), early-onset coronary artery disease (CAD; presenting as early as childhood in some), and calcific aortic valve disease.</Attribute>
                <XRef ID="NBK174884" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">APOB-Related Familial Hypercholesterolemia, Autosomal Dominant</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8588" />
                <XRef ID="8588" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24404629</ID>
                <ID Source="BookShelf">NBK174884</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="Position Statement" Abbrev="CSANZ, 2016">
                <URL>https://www.csanz.edu.au/wp-content/uploads/2017/07/Familial-Hypercholesterolaemia_ratified_-25-Nov-2016.pdf</URL>
                <CitationText>The Cardiac Society of Australia and New Zealand, Diagnosis and Management of Familial Hypercholesterolaemia – Position Statement</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Familial-Hypercholesterolemia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, APOB, LDLR, PCSK9 Pathogenic Variants (Familial Hypercholesterolemia), 2019</CitationText>
              </Citation>
              <XRef ID="C1704417" DB="MedGen" />
              <XRef ID="MONDO:0007751" DB="MONDO" />
              <XRef Type="MIM" ID="144010" DB="OMIM" />
            </Trait>
            <Trait ID="18459" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Familial hypobetalipoproteinemia 1</ElementValue>
                <XRef ID="MONDO:0014252" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hypobetalipoproteinemia, normotriglyceridemic</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acanthocytosis with hypobetalipoproteinemia</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FHBL1</ElementValue>
                <XRef Type="MIM" ID="615558" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">FHBL</ElementValue>
                <XRef Type="MIM" ID="615558" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2876" />
                <XRef ID="2876" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Individuals with biallelic APOB-related familial hypobetalipoproteinemia (APOB-FHBL) may present from infancy through to adulthood with a range of clinical symptoms including deficiency of fat-soluble vitamins and gastrointestinal and neurologic dysfunction. Affected individuals typically have plasma total cholesterol, LDL cholesterol, and apo B levels below the fifth centile for age and sex. Acanthocytosis, elevated liver enzymes, and hyperbilirubinemia may also be found. The most common clinical findings are hepatomegaly, steatorrhea, and failure to thrive / growth deficiency. In the absence of treatment, affected individuals can develop atypical pigmentation of the retina; progressive loss of deep tendon reflexes, vibratory sense, and proprioception; muscle pain or weakness; dysarthria; ataxia; tremors; and steatohepatitis, fibrosis, and rarely, cirrhosis of the liver. Individuals with a heterozygous, typically truncating pathogenic variant in APOB are usually asymptomatic with mild liver dysfunction and hepatic steatosis. However, about 5%-10% of individuals with heterozygous APOB-FHBL develop relatively more severe nonalcoholic steatohepatitis requiring medical attention and occasionally progressing to cirrhosis, albeit very rarely.</Attribute>
                <XRef ID="NBK570370" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">33983694</ID>
                <ID Source="BookShelf">NBK570370</ID>
              </Citation>
              <XRef ID="C4551990" DB="MedGen" />
              <XRef ID="MONDO:0014252" DB="MONDO" />
              <XRef Type="MIM" ID="615558" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="39760" SubmissionDate="2013-12-09" DateLastUpdated="2013-12-12" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="107730.0001_HYPOBETALIPOPROTEINEMIA, FAMILIAL" title="APOB, 4-BP DEL, NT5391_HYPOBETALIPOPROTEINEMIA, FAMILIAL" />
        <ClinVarAccession Accession="SCV000039760" DateUpdated="2013-12-12" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1992-12-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a patient with hypobetalipoproteinemia (615558) and small amounts of a truncated apoB protein (B37) in VLDL, LDL, and HDL fractions of the plasma, Young et al. (1987, 1988) found deletion of 4 nucleotides (5391_5394del4) resulting in a frameshift causing change of asn1728 to thr (N1728T) and ser1729 to stop (S1729X). The truncated apoB protein contained 1,728 amino acids. This was one of the mutant alleles in the family with hypobetalipoproteinemia first reported by Steinberg et al. (1979). Linton et al. (1992) investigated the reason for the curious finding that low levels of apoB100 were produced by the mutant allele carrying this mutation. The clue that led to the understanding of what was going on with this allele was the recognition that the proband in the family, H.J.B., as well as the other 2 compound heterozygotes, actually had 4 bona fide apoB species within their plasma lipoproteins: apoB37, apoB48, apoB100, and apoB86. Linton et al. (1992) demonstrated that the apoB86 and apoB100 were products of a single mutant apoB allele, which they designated the apoB86 allele. They showed that this allele has a 1-bp deletion in exon 26 of the APOB gene (107730.0016) and that this frameshift is responsible for the synthesis of apoB86. Nevertheless, as shown by cell culture expression studies, the apoB86 allele, which contains a premature stop codon, results in the synthesis of a full-length apoB protein. The 1-bp deletion creates a stretch of 8 consecutive adenines. Addition of a single adenine within the 8 consecutive adenines appears to take place during transcription, restoring the correct reading frame and accounting for the formation of apoB100 by the apoB86 allele. Eleven percent of the cDNA clones had an additional adenine within the stretch of 8 adenines.</Attribute>
              <Citation>
                <ID Source="PubMed">3473077</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">3399894</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">221546</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">1454832</ID>
              </Citation>
              <XRef DB="OMIM" ID="615558" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="APOB" />
          </GeneList>
          <Name>APOB, 4-BP DEL, NT5391</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">4-BP DEL, NT5391</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="107730.0001" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">HYPOBETALIPOPROTEINEMIA, FAMILIAL</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="5467834" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2022-12-31">
        <ClinVarSubmissionID localKey="NM_000384.3:c.5263_5266del|OMIM:144010;615558" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002816917" DateUpdated="2022-12-31" DateCreated="2022-12-31" Type="SCV" Version="1" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-11-09">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000384.3:c.5263_5266del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="144010" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="615558" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2714203" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2020-07-16">
        <ClinVarSubmissionID localKey="3517421|MedGen:CN182502;C1704417" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001379434" DateUpdated="2024-02-28" DateCreated="2020-07-16" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-06-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20032471</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">3473077</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">3399894</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in APOB are known to be pathogenic (PMID: 20032471). This variant has been observed to segregate with hypobetalipoproteinemia in a family (PMID: 3473077, 3399894). This variant is also known as 4-bp deletion in the apo-B gene. ClinVar contains an entry for this variant (Variation ID: 17881). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Asn1755Valfs*2) in the APOB gene. It is expected to result in an absent or disrupted protein product.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="APOB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000002.11:g.21234474_21234477del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN182502" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1704417" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14224806</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5467834" TraitType="Disease" MappingType="XRef" MappingValue="615558" MappingRef="OMIM">
        <MedGen CUI="C4551990" Name="Familial hypobetalipoproteinemia 1" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2714203" TraitType="Disease" MappingType="XRef" MappingValue="C1704417" MappingRef="MedGen">
        <MedGen CUI="C1704417" Name="Hypercholesterolemia, autosomal dominant, type B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="5467834" TraitType="Disease" MappingType="XRef" MappingValue="144010" MappingRef="OMIM">
        <MedGen CUI="C1704417" Name="Hypercholesterolemia, autosomal dominant, type B" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="39760" TraitType="Disease" MappingType="Name" MappingValue="HYPOBETALIPOPROTEINEMIA, FAMILIAL" MappingRef="Preferred">
        <MedGen CUI="C1862596" Name="Familial hypobetalipoproteinemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2714203" TraitType="Disease" MappingType="XRef" MappingValue="CN182502" MappingRef="MedGen">
        <MedGen CUI="C4551990" Name="Familial hypobetalipoproteinemia 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

